摘要
缺氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHI)是治疗慢性肾脏病(CKD)肾性贫血的新型药物。HIF-PHI作为缺氧诱导因子(HIF)稳定剂,可提高HIF表达水平,HIF的持续升高促进血管平滑肌细胞的成骨转分化和钙化,加大血管钙化的风险,长期使用HIF-PHI可能存在血管钙化的潜在风险。血管钙化是CKD患者心血管事件发病率和病死率增加的主要危险因素,因此应充分了解HIF-PHI潜在的危害性并加以重视。该文就HIF-PHI在CKD血管钙化中的研究进展进行综述。
Hypoxia-inducible factor-prolyl hydroxylase inhibitor(HIF-PHI)is a novel drug for treating renal anemia in chronic kidney disease(CKD).As a stabilizer of hypoxia-inducible factor(HIF),HIF-PHI can increase the expression level of HIF,and the continuous increase of HIF can promote the osteogenic transdifferentiation and calci-fication of vascular smooth muscle cells,which has the risk of increasing vascular calcification.Long-term use of HIF-PHI may have the potential risk of vascular calcification.Vascular calcification is a major risk factor for the increase of inci-dence rate and mortality rate of cardiovascular events in CKD patients.Therefore,the potential hazards of HIF-PHI should be fully understood and taken seriously.This paper reviews the research progress of HIF-PHI in vascular calcification in CKD.
作者
李林
尤燕舞
LI Lin;YOU Yanwu(Department of Nephrology,the People′s Hospital of Guangxi Zhuang Autonomous Region(Guangxi Academy of Medical Sciences),Nanning 530021,China)
出处
《中国临床新医学》
2024年第8期866-870,共5页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
基金
广西壮族自治区人民医院青年基金项目(编号:QN2021-12)。
关键词
缺氧诱导因子脯氨酰羟化酶抑制剂
缺氧诱导因子
血管钙化
慢性肾脏病
Hypoxia⁃inducible factor⁃prolyl hydroxylase inhibitor(HIF⁃PHI)
Hypoxia⁃inducible factor(HIF)
Vascular calcification
Chronic kidney disease(CKD)